Maria Sundvall
MD PhD; Specialist Physician in Clinical Oncology
mahesu@utu.fi Kiinamyllynkatu 10 Turku |
clinical oncology; breast and prostate cancer; targeted cancer therapeutics; cancer biology; cell signaling; posttranslational modifications; dna repair pathways
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
4 of 5
- Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor (2009)
- Neoplasia
- Somatic mutations of ErbB4: Selective loss-of-function phenotype affecting signal transduction pathways in cancer (2009)
- Journal of Biological Chemistry
- Role of ErbB4 in breast cancer (2008)
- Journal of Mammary Gland Biology and Neoplasia
- Association of Wwox with ErbB4 in breast cancer (2007)
- Cancer Research
- Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro (2007)
- Radiotherapy and Oncology
- Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains (2007)
- Oncogene
- Proteolytic cleavage and phosphorylation of tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. (2006) Määttä J.A., Sundvall M., Junttila T.T., Peri L., Isola J., Egeblad M., Elenius K.
- Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells (2006)
- Clinical Cancer Research
- Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells (2005)
- Cancer Research
- Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor (2003) Iivanainen E, Nelimarkka L, Elenius V, Heikkinen S-M, Junttila TT, Sihombin L, Sundvall M, Määttä JA, Laine VJO, Higashiyama S, Alitalo K, Elenius K
UTU Research Portal